Jennifer Cote's most recent trade in Harvard Bioscience Inc. was a trade of 5,687 Common Stock done at an average price of $0.7 . Disclosure was reported to the exchange on March 19, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Harvard Bioscience Inc. | Jennifer Cote | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.69 per share. | 19 Mar 2025 | 5,687 | 159,019 (0%) | 0% | 0.7 | 3,916 | Common Stock |
| Harvard Bioscience Inc. | Jennifer Cote | Chief Financial Officer | 29 Dec 2024 | 4,731 | 164,007 (0%) | 0% | 2.0 | 9,367 | Common Stock | |
| Harvard Bioscience Inc. | Jennifer Cote | Chief Financial Officer | 29 Dec 2024 | 3,797 | 160,210 (0%) | 0% | 2.0 | 7,518 | Common Stock | |
| Harvard Bioscience Inc. | Jennifer Cote | Chief Financial Officer | 05 Mar 2024 | 35,800 | 142,858 (0%) | 0% | 0 | Common Stock | ||
| Harvard Bioscience Inc. | Jennifer Cote | Chief Financial Officer | 05 Mar 2024 | 35,800 | 178,658 (0%) | 0% | 0 | Common Stock | ||
| Harvard Bioscience Inc. | Jennifer Cote | Chief Financial Officer | 05 Mar 2024 | 9,920 | 168,738 (0%) | 0% | 4.1 | 40,771 | Common Stock | |
| Harvard Bioscience Inc. | Jennifer Cote | Director, Chief Financial Officer | 29 Dec 2023 | 3,279 | 109,689 (0%) | 0% | 5.4 | 17,543 | Common Stock | |
| Harvard Bioscience Inc. | Jennifer Cote | Director, Chief Financial Officer | 29 Dec 2023 | 2,631 | 107,058 (0%) | 0% | 5.4 | 14,076 | Common Stock | |
| Harvard Bioscience Inc. | Jennifer Cote | Interim CFO | 06 Mar 2023 | 29,880 | 112,968 (0%) | 0% | 0 | Common Stock | ||
| Harvard Bioscience Inc. | Jennifer Cote | Interim CFO | 06 Mar 2023 | 26,892 | 57,226 (0%) | 0% | 0 | Common Stock | ||
| Harvard Bioscience Inc. | Jennifer Cote | Interim CFO | 06 Mar 2023 | 25,862 | 83,088 (0%) | 0% | 0 | Common Stock |